Last reviewed · How we verify
Sorafenib - Period 2
At a glance
| Generic name | Sorafenib - Period 2 |
|---|---|
| Also known as | Regimen A (reference) |
| Sponsor | Xspray Pharma AB |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia (PHASE2)
- Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) (PHASE2)
- Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (PHASE2)
- Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy (PHASE2)
- Evaluating the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib (XS005) in Healthy Male Subjects (PHASE1)
- Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children (PHASE2, PHASE3)
- CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma (PHASE2)
- TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |